Detalhe da pesquisa
1.
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
Blood
; 142(21): 1784-1788, 2023 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37595283
2.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Haematologica
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38695144
3.
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Am J Hematol
; 99(4): 792-796, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38361282
4.
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Cancer
; 129(4): 560-568, 2023 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36458426
5.
Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation.
Am J Hematol
; 98(9): 1383-1393, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37334870
6.
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Am J Hematol
; 98(11): 1780-1790, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37665752
7.
New Approaches to Myelodysplastic Syndrome Treatment.
Curr Treat Options Oncol
; 23(5): 668-687, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35320468
8.
Changing paradigms in the treatment of acute myeloid leukemia in older patients.
Clin Adv Hematol Oncol
; 20(1): 37-46, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35060961
9.
Advances in the management of higher-risk myelodysplastic syndromes: future prospects.
Leuk Lymphoma
; : 1-12, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38712556
10.
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
Blood Adv
; 8(4): 927-935, 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38113472
11.
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm.
Blood Adv
; 2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513082
12.
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes.
Nat Commun
; 15(1): 2428, 2024 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38499526
13.
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
Lancet Haematol
; 11(4): e287-e298, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38548404
14.
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Lancet Haematol
; 11(4): e276-e286, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38452788
15.
Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax.
Clin Cancer Res
; 30(7): 1319-1326, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38300723
16.
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Lancet Haematol
; 11(3): e186-e195, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38316133
17.
Automated quantification of measurable residual disease in chronic lymphocytic leukemia using an artificial intelligence-assisted workflow.
Cytometry B Clin Cytom
; 2023 Feb 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36824056
18.
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity.
Blood Adv
; 7(13): 3284-3296, 2023 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36884300
19.
Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
Lancet Haematol
; 9(10): e756-e765, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36063832
20.
A review of FDA-approved acute myeloid leukemia therapies beyond '7 + 3'.
Expert Rev Hematol
; 14(2): 185-197, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33430671